Abstract

A dynamic treatment regime (DTR) is a sequence of treatment decision rules that dictate individualized treatments based on evolving treatment and covariate history. It provides a vehicle for optimizing a clinical decision support system and fits well into the broader paradigm of personalized medicine. However, many real-world problems involve multiple competing priorities, and decision rules differ when trade-offs are present. Correspondingly, there may be more than one feasible decision that leads to empirically sufficient optimization. In this paper, we propose a concept of "tolerant regime," which provides a set of individualized feasible decision rules under a prespecified tolerance rate. A multiobjective tree-based reinforcement learning (MOT-RL) method is developed to directly estimate the tolerant DTR (tDTR) that optimizes multiple objectives in a multistage multitreatment setting. At each stage, MOT-RL constructs an unsupervised decision tree by modeling the counterfactual mean outcome of each objective via semiparametric regression and maximizing a purity measure constructed by the scalarized augmented inverse probability weighted estimators (SAIPWE). The algorithm is implemented in a backward inductive manner through multiple decision stages, and it estimates the optimal DTR and tDTR depending on the decision-maker's preferences. Multiobjective tree-based reinforcement learning is robust, efficient, easy-to-interpret, and flexible to different settings. We apply MOT-RL to evaluate 2-stage chemotherapy regimes that reduce disease burden and prolong survival for advanced prostate cancer patients using a dataset collected at MD Anderson Cancer Center.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.